Symbiomix Therapeutics has hired David L. Stern to become the CEO of the Newark, NJ-based drug developer. Stern previously served as chief commercial officer of New York biotech Celmatix. His experience also includes various management roles at OvaScience (NASDAQ: [[ticker:OVAS]]) and Merck Serono.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
